ALX ONCOLOGY HOLDINGS INC (ALXO) Fundamental Analysis & Valuation

NASDAQ:ALXO • US00166B1052

2.15 USD
+0.11 (+5.39%)
At close: Mar 11, 2026
2.15 USD
0 (0%)
After Hours: 3/11/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ALXO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ALXO. ALXO was compared to 519 industry peers in the Biotechnology industry. Both the profitability and financial health of ALXO have multiple concerns. ALXO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. ALXO Profitability Analysis

1.1 Basic Checks

  • In the past year ALXO has reported negative net income.
  • In the past year ALXO has reported a negative cash flow from operations.
  • In the past 5 years ALXO always reported negative net income.
  • In the past 5 years ALXO always reported negative operating cash flow.
ALXO Yearly Net Income VS EBIT VS OCF VS FCFALXO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • With a Return On Assets value of -130.57%, ALXO is not doing good in the industry: 80.92% of the companies in the same industry are doing better.
  • ALXO's Return On Equity of -241.09% is on the low side compared to the rest of the industry. ALXO is outperformed by 70.52% of its industry peers.
Industry RankSector Rank
ROA -130.57%
ROE -241.09%
ROIC N/A
ROA(3y)-65.92%
ROA(5y)-46.28%
ROE(3y)-83.34%
ROE(5y)-56.97%
ROIC(3y)N/A
ROIC(5y)N/A
ALXO Yearly ROA, ROE, ROICALXO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

  • ALXO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALXO Yearly Profit, Operating, Gross MarginsALXO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ALXO Health Analysis

2.1 Basic Checks

  • ALXO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALXO Yearly Shares OutstandingALXO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALXO Yearly Total Debt VS Total AssetsALXO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • ALXO has an Altman-Z score of -13.76. This is a bad value and indicates that ALXO is not financially healthy and even has some risk of bankruptcy.
  • ALXO's Altman-Z score of -13.76 is on the low side compared to the rest of the industry. ALXO is outperformed by 79.58% of its industry peers.
  • A Debt/Equity ratio of 0.15 indicates that ALXO is not too dependend on debt financing.
  • ALXO has a Debt to Equity ratio of 0.15. This is in the lower half of the industry: ALXO underperforms 63.39% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -13.76
ROIC/WACCN/A
WACCN/A
ALXO Yearly LT Debt VS Equity VS FCFALXO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 2.40 indicates that ALXO has no problem at all paying its short term obligations.
  • The Current ratio of ALXO (2.40) is worse than 71.68% of its industry peers.
  • A Quick Ratio of 2.40 indicates that ALXO has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.40, ALXO is doing worse than 68.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 2.4
ALXO Yearly Current Assets VS Current LiabilitesALXO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ALXO Growth Analysis

3.1 Past

  • ALXO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.15%, which is quite impressive.
EPS 1Y (TTM)31.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ALXO will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.87% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y48.15%
EPS Next 2Y26.03%
EPS Next 3Y17.71%
EPS Next 5Y10.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALXO Yearly Revenue VS EstimatesALXO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2030 2031 2032 2033 50M 100M 150M
ALXO Yearly EPS VS EstimatesALXO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4 6 8

More info and screens

Find the best growth stocksShow best growing peers

0

4. ALXO Valuation Analysis

4.1 Price/Earnings Ratio

  • ALXO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALXO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALXO Price Earnings VS Forward Price EarningsALXO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALXO Per share dataALXO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALXO's earnings are expected to grow with 17.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.03%
EPS Next 3Y17.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALXO Dividend Analysis

5.1 Amount

  • No dividends for ALXO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALXO Fundamentals: All Metrics, Ratios and Statistics

ALX ONCOLOGY HOLDINGS INC

NASDAQ:ALXO (3/11/2026, 8:00:00 PM)

After market: 2.15 0 (0%)

2.15

+0.11 (+5.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27
Earnings (Next)05-06
Inst Owners73.81%
Inst Owner Change4.61%
Ins Owners1.47%
Ins Owner Change5.06%
Market Cap116.57M
Revenue(TTM)N/A
Net Income(TTM)-108.01M
Analysts81.82
Price Target3.4 (58.14%)
Short Float %2.95%
Short Ratio2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.65%
Min EPS beat(2)-9.62%
Max EPS beat(2)6.32%
EPS beat(4)2
Avg EPS beat(4)-1.58%
Min EPS beat(4)-22.55%
Max EPS beat(4)19.52%
EPS beat(8)5
Avg EPS beat(8)4.11%
EPS beat(12)8
Avg EPS beat(12)2.17%
EPS beat(16)9
Avg EPS beat(16)-0.21%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.11%
PT rev (3m)11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.14%
EPS NY rev (3m)-0.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.6
P/tB 2.6
EV/EBITDA N/A
EPS(TTM)-1.79
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-1.8
FCFYN/A
OCF(TTM)-1.79
OCFYN/A
SpS0
BVpS0.83
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -130.57%
ROE -241.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.92%
ROA(5y)-46.28%
ROE(3y)-83.34%
ROE(5y)-56.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.4
Quick Ratio 2.4
Altman-Z -13.76
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)208.08%
Cap/Depr(5y)2095.85%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.73%
EPS Next Y48.15%
EPS Next 2Y26.03%
EPS Next 3Y17.71%
EPS Next 5Y10.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.23%
EBIT Next 3Y18.82%
EBIT Next 5YN/A
FCF growth 1Y13.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.7%
OCF growth 3YN/A
OCF growth 5YN/A

ALX ONCOLOGY HOLDINGS INC / ALXO FAQ

What is the fundamental rating for ALXO stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALXO.


What is the valuation status for ALXO stock?

ChartMill assigns a valuation rating of 0 / 10 to ALX ONCOLOGY HOLDINGS INC (ALXO). This can be considered as Overvalued.


How profitable is ALX ONCOLOGY HOLDINGS INC (ALXO) stock?

ALX ONCOLOGY HOLDINGS INC (ALXO) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for ALXO stock?

The Earnings per Share (EPS) of ALX ONCOLOGY HOLDINGS INC (ALXO) is expected to grow by 48.15% in the next year.